INTRODUCTION
In many clinical specialties including neurology, cardiology and orthopedics, implantable medical devices are frequently used. Devices like joint replacements, pain pumps and pacemakers perform an fludic, mechanical, or electronic function to lead patients to perform their normal body functions. To reduce morbidity and improve efficacy, many manufacturers of device have integrated chemicals or drugs into medical implants in the past decade. For instance when comparing the Drug-eluting stents with bare metal stents it was found that drug eluting stent reduce instent restenosis.
1
Patient compliance is a major problem where frequent dose administration is required, in these cases a health professionals are in dare need to have an automated drug delivery system. A drug delivery system can be defined as mechanism to introduce therapeutic agent into the body. Drug delivery systems have had a high impact on technology, greatly enhance the presentation of many current drugs & facilitate the use of new therapies. 2 Santini el al., first developed one class of combination products featuring ondemand drug release capabilities that was a microchip with many reservoirs containing discrete doses of drug .
3-5
Micro-electronic devices have become essential part of today"s life. They are present in our cellular phones, computers and automobiles. 6 Technology enable to develop revolutionary opportunities in every field of life and this stimulated the development of innovative techniques in drug delivery system. Recent advances in the field of drug delivery system created the possibility to meet the patient need. For this a new drug delivery system is design that is wireless control drug delivery system that work through "microchip".
7

Need of wireless drug delivery system
Wireless drug delivery system has the capability to improve patient compliance as patient compliance is a major issue, especially in chronic diseases. Such issues include "simply forgetting, that is 65%; "concerns about the drugs" that is 45%; and feeling the "drug is unnecessary" is 43%, it is just because of long term use and complex drug regimen. 8 Traditionally, research has concentrated on recognizing why patients are noncompliant and the strategies to increase compliance.
9
The pattern of treatment has been changed drastically after the emergence of programmable chips for chronic ailments patients like cancer, multiple sclerosis and osteoporosis. In conditions where frequent daily injections are needed mostly in case of chronic illnesses where regular pain management is required, can have benefits from this technology,
Therefore, if a drug delivery device is capable of being controlled from outside the body and can release many types of drugs continuously and also implantable safely in human body, will be greatly advantageous. Many factors that must be come into account for manufacturing of effective and successful drug delivery system few includes how it is being processed, reliability of material, biocompatibility and drug release pattern.
Microchips
Microchips are smart medical implants that can dispense drugs into the bloodstream by getting wireless signals sent to them from the medical implant communication service (MICS).
11
Localized delivery, delivery on demand, controlled drug release, dose checking and physician option to remotely adjust treatment schedule are advantages of these chips.
12 Implantable medical device is not a new term; such devices are in use such as pace-maker and pain pumps. 13 This smart implant can be injected under the skin in the doctor's office in about 30 minutes using a local anesthetic and lasts about four months before needing to be replaced.
14
How it works
Microchip based implants are programmed to release drugs inside the body through wireless system. This contains micro reservoir where drug is stored and it is sealed with platinum and titanium membrane. This is planted in human body under the skin and when the drug release is needed, the device is activated through wireless signal and an electrical current is applied which melt the membrane and release the drug inside the body. When drug reservoir is empty, the next dose can be delivered through another reservoir. 
CLINICAL TRIALS
Microchip based drug delivery device trial was first performed clinically in eight osteoporotic postmenopausal women where the discrete doses of lyophilized hPTH(1-34) containing devices were implanted. The dose has been released once daily through wireless controlled drug delivery system for 20 days. The hPTH(1-34) was analyzed for bioequivalence, safety, tolerability and pharmacokinetics. It is revealed that release of drug from device on daily basis increased bone formation. No adverse effect or toxicity seen and device did not affect quality of life.
16
Application of WDDS in Osteoporosis:
Osteoporosis is treated by Human parathyroid hormone fragment [hPTH(1-34)]. It occurs if the balance of bone resorption and formation process disturbed. In osteoporosis bone mineral density is lost which causes bone fractures. According to World Health Organization about 9 million fractures per year in the world are due to osteoporosis, and contribute significantly to disability rates. 17 The projected cost of these fractures in US is estimated as more than $20 billion . 18 The drugs used to treat osteoporosis are classified in two classes, one type is bone resorption inhibitors that include calcitonin, bisphosphonates, and estrogens, , and the second type are
19
Regular hPTH(1-34) administration encourage osteoclast activity, which casue bone loss.
20, 21 On the other hand, intermittent or pulsatile delivery of hPTH(1-34) is used as anabolic therapy and incite osteoblast activity (bone formation) greater than osteoclast activity, and so the bone mineral density and mass increased. 22 Daily administration of 20-to 40-mg doses of hPTH (1-34) through subcutaneous route for around 2 years cause a decrease in fracture incidence and it is with acceptable profile of safety.
23, 24 But the patient compliance for daily subcutaneous injections is poor.
25
The first candidate which was selected for human trial was hPTH(1-34). The programmable implant was used in clinical trials that deliver hPTH(1-34) at scheduled intervals, with a similar PK value as in case of daily subcutaneous injections. 
CHALLENGES AND OPPORTUNITIES
Although the microchips based wireless drug delivery system seems to be perfect for patients with chronic ailments but there are some problems in the commercial development of these devices that includes:
 complexity (as multiple system interaction is required, and failure risk is higher),  cost is high  potentially harmful (a minor surgery is needed)  obtrusive (existing device has a large size) and  Limitation in drug loading (only few drugs are feasible to be loaded for a long therapy). Like every other technology, these factors will have to be eliminated and the factors for success of this technology will be:  validated proof that technology is feasible,  an approval from regulatory body  more stress advanced new delivery systems  capability to meet important medical requirement
SUBJECTS AND METHOD:
A brief awareness to the WDDS has been given to the patients and then the study was performed. A questionnaire has been prepared after reviewing literature in view of objective of study based quantitative approach. The data has been collected from patients at random who are under treatment at primary, secondary and tertiary health care units by a cross sectional study among three different categories of participants those might be the main stakeholder for future use of WDDS. Study design of data collection is shown in Figure 3. A total of 267 patients were approached out of which 203 were agreed participated in the survey. For each category of participants 50 were randomly selected to fill questionnaire forms for data collection and compilation. The participants were required to fill a structured questionnaire comprising of 20 questions. It covered all aspects of Wireless Drug delivery system (WDDS) and its future use in the patients with chronic illnesses In addition to these questions, personal profile of patients such as name, age group, occupation was asked. Name and occupation declaration was optional because it may cause reluctance to give actual information. An additional space was provided for comment and feedback.
INFORMED CONSENT:
The objective of this survey was explained after giving a brief introduction to WDDS and verbal consent was obtained from the patients. It was also informed that the data will be used for survey purpose only. Most of the participant filled the questionnaire on their own and few were interviewed as well to assist them in filling the questionnaire. 
RESULTS:
A total of 203 patients were responded to participate in the survey out of 267 approached patients (response factor was 76 %). The samples were selected in such a way that from each category 50 participants filled the questionnaire and responses were recorded. The results showed that greater percentage of participants agreed that new technological advancement is making their life easier and comfortable. About 87 % of the patients think that this statement is right. 65% of participant think that new advancement in the field of drug development will be beneficial for them among those highest positive thinkers were diabetic patients.
Figure 4: Confidence level of chronic ailment patients on technological advancement in Karachi, Pakistan
A half of the participants believe that surgical procedure can be a better option for medication intake. Patients who think that minor surgery is a better option to take a medicine instead of taking medication for years through injection was about 82 %. More than 50 % patients have the idea that this system will be with technical problems.
DISCUSSION:
The survey revealed that most of the chronic ailment patients in Karachi, Pakistan will response in affirmative for the adaptability of new technology. For the purpose of ease in taking medication, overall they prefer to go through a minor surgery instead of taking daily injections. A surprising but good thing which has been revealed that for the matter of adapting this new technology they will not blindly trust on their physician but it will the case of acceptability only if they have strong data and/or observed someone used it personally. It has two possible options either they are not eager to take risk or they want to have knowledge by themselves. 
